Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
复制标题
DOI：
10.3390/cancers13050989
复制
发表时间：
2021-02-27
期刊：
影响因子：
5.2
通讯作者：
Ma PC
中科院分区：
文献类型：
--
作者：
Albandar HJ;Fuqua J;Albandar JM;Safi S;Merrill SA;Ma PC
本研究探讨了癌症检查点免疫治疗下免疫相关不良事件 (irAE) 的真实经验和发生情况，以及其治疗再挑战状态与其对临床结果的影响之间的关系。目前的研究表明，与 irAE 相关治疗中断后未重新开始 ICI 治疗的患者相比，在癌症免疫治疗中，irAE 相关中断后重新开始免疫检查点抑制剂 (ICI) 与生存结果的显着改善无关。简介：人们越来越认识到免疫检查点疗法中的免疫相关不良事件 (irAE) 与某些恶性肿瘤的治疗结果相关。目前指导 irAE 治疗再挑战管理的数据或共识有限。方法：我们根据 IRB 批准的方案对 2011 年至 2019 年间在西弗吉尼亚大学癌症研究所就诊、组织病理学诊断为活动性癌症并接受免疫检查点抑制剂 (ICI) 治疗的成年患者进行了回顾性分析。结果：癌症类型内 ICI 中断的 irAE 组之间的人口统计学相似。总体而言，在接受 ICI 审查的 548 名患者中，有 133 例发现任何级别的 ≥1 irAE 病例。与抗 PD-1 ICI 相比，使用抗 CTLA-4 抑制剂 ICI 治疗可降低死亡风险。对于irAE阳性患者，观察到的总生存期在重新给药组（37.8个月，有/无中断地重新开始；38.6个月，中断后重新开始）和中断/非重新开始（即停药）组（24.9个月）之间没有统计学显着性，数字趋势有利于前者。结论：我们的探索性研究并未发现接受 ICI 治疗的阿巴拉契亚西弗吉尼亚州成年癌症患者中发生 irAE 并在中断后重新开始治疗的患者与未重新开始治疗的患者相比，生存结果存在显着差异。
This study examined the real-world experience and occurrence of immune-related adverse events (irAEs) under cancer checkpoint immunotherapy, and the relationship between its treatment rechallenge status and their impact on clinical outcomes. The current study demonstrates that immune checkpoint inhibitors (ICI) reinitiation after an irAE-related interruption in the setting of cancer immunotherapy was not associated with significantly improved survival outcome when compared with those without ICI treatment reinitiation after irAE-related therapy interruption. Introduction: There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. There are currently limited data or consensus to guide management of irAEs with regards to treatment rechallenge. Methods: We conducted a retrospective analysis with an IRB-approved protocol of adult patients seen at the WVU Cancer Institute between 2011–2019 with a histopathologic diagnosis of active cancers and were treated with immune checkpoint inhibitors (ICI) therapy. Results: Demographics were similar between the ICI interrupted irAE groups within cancer types. Overall, out of 548 patients who received ICI reviewed, there were 133 cases of ≥1 irAE found of any grade. Being treated with anti-CTLA-4 inhibitor ICI was associated with lower risk of death compared to anti-PD-1 ICI. The overall survival difference observed for irAE positive patients, between rechallenged (37.8 months, reinitiated with/without interruption; 38.6 months, reinitiated after interruption) and interrupted/non-reinitiated (i.e., discontinued) groups (24.9 months) was not statistically significant, with a numerical trend favoring the former. Conclusions: Our exploratory study did not identify significantly different survival outcomes among the Appalachian West Virginia adult cancer patients treated with ICI who developed irAE and had treatment reinitiated after interruption, when compared with those not reinitiated.
登录
查看更多内容
影响因子：
3.6
作者：
Owen DH;Wei L;Bertino EM;Edd T;Villalona-Calero MA;He K;Shields PG;Carbone DP;Otterson GA
通讯作者：
Otterson GA
晚期黑色素瘤中尼伐单抗加伊匹单抗或单用尼伐单抗与单用伊匹单抗的比较（CheckMate 067）： 多中心、随机、3 期试验的 4 年结果
影响因子：
51.1
作者：
Hodi, Frank Stephen;Chiarion-Sileni, Vanna;Wolchok, Jedd D.
通讯作者：
Wolchok, Jedd D.
DOI：
10.1158/1078-0432.ccr-14-1429
发表时间：
2015-03-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Jamal-Hanjani M;Quezada SA;Larkin J;Swanton C
通讯作者：
Swanton C
影响因子：
45.3
作者：
Reck, Martin;Rodriguez-Abreu, Delvys;Brahmer, Julie R.
通讯作者：
Brahmer, Julie R.
影响因子：
5.8
作者：
Suo, Aleksi;Chan, Yin;Cheng, Tina
通讯作者：
Cheng, Tina